৳ 80/unit
Pack: ৳ 800
৳ 80/unit
Pack: ৳ 800
At a glance
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Indications
- Moderate-to-severe plaque psoriasis (adults, candidates for systemic therapy or phototherapy)
Pharmacology
Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of STATs.
Dosage
Adult: 6 mg once daily orally, with or without food. Do not crush, cut, or chew the tablets.
Severe hepatic impairment (Child-Pugh C): Not recommended.
Side effects
Common: Upper respiratory infections (common cold, sore throat, sinus infection), herpes simplex (cold sores), aphthous ulcers (canker sores), folliculitis, acne.
Serious: Allergic reactions (angioedema, breathing difficulty, rash, hives).
Use in pregnancy
Available data on Deucravacitinib use during pregnancy are insufficient. No effect on embryo-fetal development was seen in animal reproductive studies.
Pregnancy Category: N/A — always consult a doctor before taking during pregnancy.
Precautions & warnings
Avoid use in active or serious infection; evaluate for TB prior to treatment; avoid live vaccines; monitor liver enzymes and triglycerides; discontinue if hypersensitivity occurs; avoid use in severe hepatic impairment.
Overdose effects
Treatment of overdose should be symptomatic.
Storage conditions
Keep below 30°C temperature, away from light & moisture. Keep out of reach of children.